BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zadavotide guraxetan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zadavotide guraxetan\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06402331-11154@assetmemo.bio
DTSTAMP:20261121T005920Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Zadavotide guraxetan: Phase 2 readout est. (NCT06402331)
DESCRIPTION:Zadavotide guraxetan\, phase 2\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSM
 A-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)\nEstima
 ted primary completion: 23 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06402331
URL:https://assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909825-11154@assetmemo.bio
DTSTAMP:20261121T005920Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Zadavotide guraxetan: Phase 2 readout est. (NCT06909825)
DESCRIPTION:Zadavotide guraxetan\, phase 2\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Pati
 ents With Metastatic Castration-Resistant Prostate Cancer (mCRPC)\nEstimat
 ed primary completion: May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zadavotide-guraxetan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06909825
URL:https://assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07611110-11154@assetmemo.bio
DTSTAMP:20261121T005920Z
DTSTART;VALUE=DATE:20290604
DTEND;VALUE=DATE:20290605
SUMMARY:Zadavotide guraxetan: Phase 3 readout est. (NCT07611110)
DESCRIPTION:Zadavotide guraxetan\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: AZD2265 Compared With Standard of Care in PSMA-
 positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)\nEsti
 mated primary completion: 4 June 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/zadavotide-guraxetan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07611110
URL:https://assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07590934-11154@assetmemo.bio
DTSTAMP:20261121T005920Z
DTSTART;VALUE=DATE:20290925
DTEND;VALUE=DATE:20290926
SUMMARY:Zadavotide guraxetan: Phase 1/2 readout est. (NCT07590934)
DESCRIPTION:Zadavotide guraxetan\, phase 1/2.\nStudy: Phase Ib/II Platform 
 Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prost
 ate Cancer\nEstimated primary completion: 25 September 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/zadavotide-guraxetan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07590934
URL:https://assetmemo.bio/drug/zadavotide-guraxetan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
